Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01295112 · ClinicalTrials.gov registry record · Phase 2
Effect of Ozurdex® 0.7 mg on Improvement of Efficacy of Bevacizumab for Central Retinal Vein Occlusion
A Phase 2 study, sponsored by Texas Retina Associates.
- Completed
- Registry status
- Phase 2
- Development phase
- 68
- Enrollment target
NCT01295112 is a Phase 2 study that has completed, run by Texas Retina Associates. The registered enrollment target is 68 participants.
The verdict
NCT01295112, a Phase 2 study, has completed, sponsored by Texas Retina Associates.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 68 participants
- Enrollment target
Study Summary
This is a study designed to determine if the addition of Ozurdex® to bevacizumab (Avastin®) eye injections reduces the need for repeat bevacizumab eye injections in patients with nonischemic central retina vein occlusion.
Interventions
- DRUG Active bevacizumab and Sham dexamethasone
- DRUG Active bevacizumab and Active dexamethasone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2011-05 |
| Est. Completion | 2015-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01295112
The ClinicalTrials.gov registry entry for NCT01295112 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Texas Retina Associates, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Active bevacizumab and Sham dexamethasone is the first listed.
NCT01295112 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01295112 about?
NCT01295112 is a clinical study titled "Effect of Ozurdex® 0.7 mg on Improvement of Efficacy of Bevacizumab for Central Retinal Vein Occlusion". This is a study designed to determine if the addition of Ozurdex® to bevacizumab (Avastin®) eye injections reduces the need for repeat bevacizumab eye injections in patients with nonischemic central retina vein occlusion.
What is the current status of trial NCT01295112?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 68 participants. The study started on 2011-05. Estimated completion is 2015-10.
What interventions are being tested in trial NCT01295112?
The interventions under investigation include: Active bevacizumab and Sham dexamethasone (DRUG), Active bevacizumab and Active dexamethasone (DRUG).
Who is sponsoring clinical trial NCT01295112?
This trial is sponsored by Texas Retina Associates, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.